California State Teachers Retirement System Purchases 48,980,106 Shares of IQVIA Holdings Inc. $IQV

California State Teachers Retirement System boosted its position in IQVIA Holdings Inc. (NYSE:IQV) by 18,735.4% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 49,241,537 shares of the medical research company’s stock after purchasing an additional 48,980,106 shares during the period. California State Teachers Retirement System owned approximately 0.30% of IQVIA worth $9,514,450,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of IQV. Wedmont Private Capital bought a new position in shares of IQVIA in the 2nd quarter worth about $203,000. HB Wealth Management LLC boosted its position in shares of IQVIA by 26.5% during the 2nd quarter. HB Wealth Management LLC now owns 5,697 shares of the medical research company’s stock valued at $1,101,000 after purchasing an additional 1,192 shares in the last quarter. Saudi Central Bank grew its stake in IQVIA by 89.0% during the second quarter. Saudi Central Bank now owns 11,879 shares of the medical research company’s stock worth $2,295,000 after purchasing an additional 5,593 shares during the period. AlphaGrep UK Ltd acquired a new stake in IQVIA during the second quarter worth approximately $531,000. Finally, Munich Reinsurance Co Stock Corp in Munich bought a new stake in IQVIA in the second quarter worth approximately $1,020,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Trading Down 3.1%

NYSE IQV opened at $259.49 on Wednesday. The company has a market cap of $42.71 billion, a price-to-earnings ratio of 32.19, a P/E/G ratio of 2.29 and a beta of 1.18. IQVIA Holdings Inc. has a 52 week low of $154.50 and a 52 week high of $271.80. The business has a 50 day moving average price of $233.34 and a 200-day moving average price of $194.19. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. During the same period in the prior year, the firm earned $2.81 earnings per share. IQVIA’s revenue for the quarter was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, equities analysts expect that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Wall Street Zen cut IQVIA from a “buy” rating to a “hold” rating in a report on Saturday, August 29th. Mizuho boosted their target price on shares of IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Stifel Nicolaus increased their target price on shares of IQVIA from $220.00 to $276.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. BMO Capital Markets raised their price target on shares of IQVIA from $210.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. Finally, Barclays reaffirmed an “overweight” rating on shares of IQVIA in a research note on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and an average price target of $243.62.

Insider Activity

In other IQVIA news, insider Eric Sherbet sold 5,000 shares of the firm’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the transaction, the insider directly owned 20,999 shares of the company’s stock, valued at approximately $5,232,110.84. This trade represents a 19.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Bhavik Patel sold 1,855 shares of IQVIA stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the transaction, the insider owned 1,348 shares of the company’s stock, valued at $317,143.96. This represents a 57.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 15,581 shares of company stock valued at $3,796,021. 1.70% of the stock is currently owned by insiders.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.